Survival and safety of treatment with infliximab in the elderly population.

作者信息

Chevillotte-Maillard H, Ornetti P, Mistrih R, Sidot C, Dupuis J, Dellas J-A, Tavernier C, Maillefert J F

出版信息

Rheumatology (Oxford). 2005 May;44(5):695-6. doi: 10.1093/rheumatology/keh562. Epub 2005 Feb 10.

DOI:10.1093/rheumatology/keh562

PMID:15705631

Abstract

摘要

相似文献

Survival and safety of treatment with infliximab in the elderly population.

Rheumatology (Oxford). 2005 May;44(5):695-6. doi: 10.1093/rheumatology/keh562. Epub 2005 Feb 10.

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

Rheumatology (Oxford). 2005 May;44(5):670-6. doi: 10.1093/rheumatology/keh584. Epub 2005 Mar 9.

[TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports].

Lakartidningen. 2005;102(49):3788-90, 3793.

[Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].

Tidsskr Nor Laegeforen. 2005 Jun 16;125(12):1664-6.

Infliximab treatment in ankylosing spondylitis: an observational study.

Ann Rheum Dis. 2005 Jun;64(6):940-2. doi: 10.1136/ard.2004.029900. Epub 2004 Nov 25.

Tuberculosis and anti-TNF-alpha treatment.

Thorax. 2004 Nov;59(11):921. doi: 10.1136/thx.2004.029991.

Development of sarcoidosis during etanercept therapy.

Arthritis Rheum. 2006 Oct 15;55(5):817-20. doi: 10.1002/art.22238.

Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.

Am J Med. 2005 May;118(5):552-6. doi: 10.1016/j.amjmed.2005.01.028.

Tuberculous peritonitis.

Am J Gastroenterol. 2005 Jul;100(7):1624-5. doi: 10.1111/j.1572-0241.2005.50006_8.x.

Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.

Isr Med Assoc J. 2008 Apr;10(4):277-81.

引用本文的文献

Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.

J Clin Med. 2022 Jul 29;11(15):4422. doi: 10.3390/jcm11154422.

Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis.

Sci Rep. 2021 Nov 3;11(1):21555. doi: 10.1038/s41598-021-01132-6.

Does Older Age have an Impact on Rituximab Efficacy and Safety? Results from the NOR-DMARD Register.

Drugs Aging. 2020 Aug;37(8):617-626. doi: 10.1007/s40266-020-00782-x.

Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis.

Can Geriatr J. 2020 May 1;23(2):184-189. doi: 10.5770/cgj.23.393. eCollection 2020 Jun.

How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol.

Rheumatol Int. 2019 Feb;39(2):395-398. doi: 10.1007/s00296-018-4205-z. Epub 2018 Nov 24.

Elderly patients and inflammatory bowel disease.

World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):51-65. doi: 10.4292/wjgpt.v7.i1.51.

Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs.

Drugs Aging. 2016 Feb;33(2):97-107. doi: 10.1007/s40266-015-0341-2.

Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations.

Drugs Aging. 2015 Jul;32(7):515-24. doi: 10.1007/s40266-015-0280-y.

Elderly-onset sarcoidosis: prevalence, clinical course, and treatment.

Drugs Aging. 2013 Dec;30(12):969-78. doi: 10.1007/s40266-013-0125-5.

Old-age inflammatory bowel disease onset: a different problem?

World J Gastroenterol. 2011 Jun 14;17(22):2734-9. doi: 10.3748/wjg.v17.i22.2734.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验